- Home
- PRFX vs NDRA Comparison
PRFX vs NDRA Comparison
Compare PRFX & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRFX
- NDRA
- Stock Information
- Founded
- PRFX 2007
- NDRA 2007
- Country
- PRFX Israel
- NDRA United States
- Employees
- PRFX N/A
- NDRA N/A
- Industry
- PRFX Biotechnology: Pharmaceutical Preparations
- NDRA Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- PRFX Health Care
- NDRA Health Care
- Exchange
- PRFX Nasdaq
- NDRA Nasdaq
- Market Cap
- PRFX 2.8M
- NDRA 3.1M
- IPO Year
- PRFX 2020
- NDRA 2017
- Fundamental
- Price
- PRFX $1.34
- NDRA $4.91
- Analyst Decision
- PRFX Hold
- NDRA Strong Buy
- Analyst Count
- PRFX 1
- NDRA 1
- Target Price
- PRFX N/A
- NDRA $46.00
- AVG Volume (30 Days)
- PRFX 8.8M
- NDRA 30.3K
- Earning Date
- PRFX 09-26-2025
- NDRA 11-14-2025
- Dividend Yield
- PRFX N/A
- NDRA N/A
- EPS Growth
- PRFX N/A
- NDRA N/A
- EPS
- PRFX N/A
- NDRA N/A
- Revenue
- PRFX N/A
- NDRA N/A
- Revenue This Year
- PRFX N/A
- NDRA N/A
- Revenue Next Year
- PRFX N/A
- NDRA N/A
- P/E Ratio
- PRFX N/A
- NDRA N/A
- Revenue Growth
- PRFX N/A
- NDRA N/A
- 52 Week Low
- PRFX $1.25
- NDRA $2.90
- 52 Week High
- PRFX $16.63
- NDRA $22.68
- Technical
- Relative Strength Index (RSI)
- PRFX 44.57
- NDRA 57.78
- Support Level
- PRFX $1.32
- NDRA $4.00
- Resistance Level
- PRFX $1.47
- NDRA $4.69
- Average True Range (ATR)
- PRFX 0.12
- NDRA 0.35
- MACD
- PRFX -0.02
- NDRA 0.11
- Stochastic Oscillator
- PRFX 4.17
- NDRA 70.98
About PRFX PainReform Ltd.
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
About NDRA ENDRA Life Sciences Inc.
ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.